1538 Participants Needed

N-803 + Standard Care for Non-Small Cell Lung Cancer

Recruiting at 30 trial locations
BG
JG
BG
PB
BF
Overseen ByBruno Fang, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you must stop taking your current medications. However, you cannot take medications that have an adverse reaction with the study drugs. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug combination N-803 + Standard Care for Non-Small Cell Lung Cancer?

Research shows that combining pembrolizumab with carboplatin and nab-paclitaxel significantly improved survival rates in patients with advanced non-small cell lung cancer, suggesting that similar combinations could be effective.12345

What safety data exists for N-803 + Standard Care for Non-Small Cell Lung Cancer?

Research shows that treatments involving nab-paclitaxel (a form of chemotherapy) combined with carboplatin have been studied for safety in non-small cell lung cancer. These studies generally focus on the safety and side effects of these drugs, which are important to consider when evaluating treatment options.12346

What makes the drug combination of N-803, Carboplatin, Nab-paclitaxel, Pembrolizumab, and Pemetrexed unique for treating non-small cell lung cancer?

This drug combination is unique because it includes N-803, an IL-15 superagonist complex, which is designed to boost the immune system's response against cancer cells, alongside a mix of chemotherapy agents like Carboplatin, Nab-paclitaxel, and Pemetrexed, and the immunotherapy drug Pembrolizumab, which helps the immune system recognize and attack cancer cells. This multi-faceted approach aims to enhance treatment effectiveness by combining immune system activation with traditional chemotherapy.12347

What is the purpose of this trial?

This trial tests N-803 with standard treatments for patients with severe lung cancer. N-803 aims to boost the immune system to fight cancer cells more effectively.

Research Team

PB

Paula Bradshaw

Principal Investigator

Vice President, Clinical Business Operations

Eligibility Criteria

This trial is for adults with stage 3 or 4 non-small cell lung cancer (NSCLC) who haven't had systemic chemotherapy for advanced/metastatic NSCLC. They must have tumors without certain genetic mutations, measurable tumor lesions, and an ECOG performance status of 0 or 1. Participants need to provide consent, tissue samples, agree to contraception use if applicable, and not be candidates for surgery or chemoradiation.

Inclusion Criteria

My tumor does not have specific genetic changes in EGFR, ALK, BRAF, ROS1, or NTRK.
Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines
The tumor can be measured and evaluated using a specific method called RECIST 1.1.
See 9 more

Exclusion Criteria

Known hypersensitivity to any component of the study medication(s)
I have a history of HIV or active hepatitis B or C.
I have or had inflammatory bowel disease like Crohn's or ulcerative colitis.
See 17 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive N-803 in combination with chemoimmunotherapy containing approved CPIs as first-line treatment for up to 2 years

Up to 104 weeks

Follow-up

Participants are monitored for disease progression, post-therapies, and survival

24 months

Treatment Details

Interventions

  • Carboplatin
  • N-803
  • Nab-paclitaxel
  • Pembrolizumab
  • Pemetrexed
Trial Overview The study compares the safety and effectiveness of N-803 combined with standard cancer treatments versus the standard treatments alone in NSCLC patients. It's a phase 3 trial where treatment continues up to two years unless there are issues like disease progression or unacceptable side effects.
Participant Groups
7Treatment groups
Experimental Treatment
Active Control
Group I: Cohort D (Experimental)Experimental Treatment1 Intervention
Group II: Cohort C (Experimental)Experimental Treatment1 Intervention
Group III: Cohort B (Experimental)Experimental Treatment1 Intervention
Group IV: Cohort A (Experimental)Experimental Treatment1 Intervention
Group V: Cohort A (Control)Active Control1 Intervention
Group VI: Cohort B (Control)Active Control1 Intervention
Group VII: Cohort C (Control)Active Control1 Intervention

Carboplatin is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Paraplatin for:
  • Ovarian cancer
  • Testicular cancer
  • Lung cancer
  • Head and neck cancer
  • Brain cancer
🇪🇺
Approved in European Union as Carboplatin for:
  • Ovarian cancer
  • Small cell lung cancer
🇨🇦
Approved in Canada as Carboplatin for:
  • Ovarian cancer
  • Small cell lung cancer
  • Testicular cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

ImmunityBio, Inc.

Lead Sponsor

Trials
75
Recruited
5,000+

Richard Adcock

ImmunityBio, Inc.

Chief Executive Officer since 2024

Information not available

Dr. Patrick Soon-Shiong

ImmunityBio, Inc.

Chief Medical Officer since 2021

MD

Findings from Research

The combination of pemetrexed and nab-paclitaxel was found to be feasible and well tolerated in patients with advanced non-small cell lung cancer (NSCLC), with a recommended phase II dose established at pemetrexed 500 mg/m² and nab-paclitaxel 260 mg/m².
In a phase II trial involving 37 patients, the treatment showed a response rate of 14% and a disease control rate of 46%, with a median overall survival of 8.8 months, indicating some efficacy in second and third-line therapy despite the early closure of the study.
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.Ho, C., Davies, AM., Sangha, RS., et al.[2023]
In a phase III trial involving 1,052 patients with advanced non-small-cell lung cancer, nab-paclitaxel plus carboplatin showed a significantly higher overall response rate (33%) compared to solvent-based paclitaxel plus carboplatin (25%), indicating greater efficacy in treatment.
Nab-paclitaxel was associated with fewer severe side effects, such as neuropathy and neutropenia, compared to solvent-based paclitaxel, suggesting it may be a safer option for patients.
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.Socinski, MA., Bondarenko, I., Karaseva, NA., et al.[2022]
Nab-paclitaxel significantly improves overall response (OR) and partial response (PR) rates in advanced non-small cell lung cancer (NSCLC), especially in squamous cell carcinoma and as a second-line treatment, based on a meta-analysis of 35 studies involving various trial designs.
While nab-paclitaxel shows marginal improvements in overall survival (OS) and progression-free survival (PFS), the evidence regarding its safety profile and reduction of adverse events remains inconclusive, indicating a need for further research.
Efficacy and safety of nanoparticle albumin-bound paclitaxel in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials and observational studies.Suwannasom, N., Sriaksorn, N., Thepmalee, C., et al.[2023]

References

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. [2023]
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. [2022]
Efficacy and safety of nanoparticle albumin-bound paclitaxel in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials and observational studies. [2023]
Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer. [2022]
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. [2020]
Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). [2015]
Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security